The Assessment of Prednisone In Remission Trial (TAPIR)

The Assessment of Prednisone In Remission Trial (TAPIR)

Brief description of study

The purpose of this study is to collect information about 2 different recommended treatments for granulomatosis with polyangiitis (GPA, Wegener’s). We want to find out whether patients with GPA do better if they stay on a maintenance dose of 5 mg of prednisone or come off of prednisone after GPA is well-controlled. There are 5 study visits and patients will be in the study for no longer than 18 months. To join this study, patients must have a GPA diagnosis and be taking prednisone.

Detailed description of study

Patients who are eligible may be enrolled when their daily dose of prednisone is between 5 mg and 20 mg. Everyone in this study will have their dose of prednisone decreased, unless they enter the study at 5 mg. Some patients will be randomized to decrease their prednisone to 0 mg, others to decrease or maintain their prednisone to 5 mg daily. Randomization means that the decision as to which option a person will receive is decided "by chance," not choice, like tossing a coin.  Patients will complete surveys, have physical exams, and information from their medical record will be collected.  This study is a project of the Vasculitis Clinical Research Consortium (VCRC), which is a network of investigators in major North American vasculitis centers.  The VCRC is funded through the National Institutes of Health as a Rare Diseases Clinical Research Network with the purpose of promoting research in vasculitis. 

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Vasculitis,Granulomatosis with Polyangiit,GPA,Wegeners
  • Age: Between 18 Years - 90 Years
  • Gender: All


Updated on 08 Jul 2023. Study ID: 818769

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center